查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465179

进行性肌肉骨化症市场：按产品、给药途径和最终用户 - 全球预测 2024-2030

Fibrodysplasia Ossificans Progressiva Market by Offering (Drug Type, Treatment), Route of Administration (Oral, Parenteral, Topical), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年进行性肌肉骨化症的市场规模为4.7046亿美元，2024年达到4.9459亿美元，2030年达到6.7565亿美元，复合年增长率预计为5.30%。

进行性肌肉骨化症(FOP) 是一种严重且严重的遗传性疾病，其特征是肌肉、韧带和结缔组织等软组织逐渐被骨骼取代（骨化）。在此过程中，骨骼外部形成骨骼，限制运动。该疾病是由ACVR1基因突变引起的，该基因突变会影响人体的修復机制，导致纤维组织在损伤或受伤后取代骨骼。进行性肌肉骨化症的全球发生率不断增加，扩大了对进行进行性肌肉骨化症不良相关治疗的需求。医疗保健专业人员和公众意识的提高，以及政府机构对罕见疾病的资金和支持的增加，正在导致诊断和治疗方法选择的改善，支持市场成长。开发有效的 FOP治疗方法的高昂研发成本以及核准治疗罕见疾病的药物的严格监管流程正在阻碍市场成长。基因研究和标靶治疗方法的进步为进行进行性肌肉骨化症相关的突破性治疗方法提供了潜力，正在为市场成长创造机会。

主要市场统计
基准年[2023] 47046万美元
预测年份 [2024] 4.9459 亿美元
预测年份 [2030] 67565万美元
复合年增长率（%） 5.30%

越来越需要 parvarotene 来抑制所提供的 FOP 中异位性骨化症的进展

非类固醇消炎剂(NSAID) 通常用于控制 FOP 患者发作时的疼痛和肿胀。儘管这些药物不能阻止疾病的进展，但它们可以透过减少不适来显着改善患者的生活品质。双磷酸盐是一种抑制骨质流失的药物。用于减缓 FOP 患者的骨骼变化。双磷酸盐在 FOP 中的有效性仍在调查中，并且正在进行研究以更好地了解其在疾病管理中的作用。皮质类固醇用于发作的早期阶段，以减轻发炎和组织肿胀。皮质类固醇的使用对于急性治疗至关重要，但由于可能存在长期副作用，因此通常只能短期使用。 Parovarotene 是一种维生素A酸受体 γ促效剂，可望抑制 FOP异位性骨化症的进展。 Parovarotene 是 FOP 治疗的一个重要突破，为改善这种疾病的治疗带来了希望。药物治疗仍然是 FOP 治疗的基石，可以解决症状、控制疼痛，如果使用含有 parovarotene 的药物，还可能减缓疾病进展。药物治疗的选择需要仔细考虑个别患者的病情和疾病阶段。职能治疗在维持 FOP 患者的活动能力和生活品质方面发挥重要作用。职能治疗师与患者合作，制定日常活动策略，尽量减少受影响区域的压力，防止疾病发作并解决疾病引起的限制。由于诱发进一步骨化的风险，FOP 患者的手术需谨慎进行。通常仅当骨骼异常导致严重损伤或危及生命的问题并且无法保守治疗时才使用手术。每个病例都需要仔细评估，以平衡手术的好处与恶化病情的可能性。

最终使用者：医院中大量使用进行进行性肌肉骨化症药物用于 FOP 的诊断、治疗和持续管理

医院是进行进行性肌肉骨化症(FOP) 的重要第一线最终使用者。这些设施是 FOP 诊断、治疗和持续管理的主要中心。鑑于 FOP 的复杂性，医院通常会协调多学科治疗团队，包括遗传学、整形外科和内分泌学专家，以解决与 FOP 相关的各种进行性症状。医院在为行动不便或呼吸困难的 FOP 患者提供紧急治疗方面也发挥着至关重要的作用。研究机构对于促进 FOP 的理解和治疗至关重要。我们正在努力透过深入研究 FOP 的遗传、分子和细胞背景来发现新的治疗标靶和策略。这些实体是评估新治疗方法有效性和安全性的临床试验的支柱。研究机构和製药商之间的合作对于将创新治疗方法从实验室带到临床至关重要。此外，研究机构经常带头进行教育倡议，以传播 FOP 意识并教育医学界和公众。专科诊所在进行进行性肌肉骨化症治疗生态系中发挥独特的作用。这些诊所通常由具有 FOP 专业知识的多学科团队运营，根据 FOP 患者的复杂需求提供专门护理。从遗传咨询和物理治疗到先进的疼痛管理和疾病进展监测，专科诊所提供一系列护理，旨在提高生活品质并减少与 FOP 相关的併发症。我们也促进患者和家庭之间的社区，并提供治疗以外的支持。

区域洞察

美洲 FOP 市场的特点是先进的医疗基础设施和专注于罕见疾病治疗的研发生态系统。还有多个意识计划和患者支持组织支持研究经费和患者护理。 FDA 指定的孤儿药等监管激励措施加快了新治疗方法的核准流程，并使美洲成为 FOP治疗方法开发和商业化的重要地区。在亚太地区，人们对包括 FOP 在内的罕见疾病的认识不断提高，诊断率不断提高。由于中国、日本和澳洲等国家医疗保健系统的改善和医疗保健支出的增加，该市场正在逐渐发展。然而，挑战依然存在，例如获得治疗的机会有限以及缺乏针对罕见疾病的专门医疗设施。欧洲、中东和非洲地区的 FOP 市场多元化，欧洲在临床研究、药物开发和患者支持活动方面处于领先地位。欧洲国家受益于强大的公共卫生保健系统和鼓励罕见疾病研究的政策，包括对罕见疾病药物开发的大量资金和奖励。该市场由政府、研究机构和製药公司之间的协作系统支援。同时，中东和非洲面临更严峻的挑战，包括认识低、研究少、获得治疗的机会有限。然而，持续努力改善医疗基础设施和建立罕见疾病治疗的国际合作是非洲市场未来的积极指标。

FPNV定位矩阵

FPNV 定位矩阵对于评估进行进行性肌肉骨化症市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对进行进行性肌肉骨化症市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.进行性肌肉骨化症市场的市场规模与预测为何？

2.在进行进行性肌肉骨化症市场预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.进行性肌肉骨化症市场的技术趋势和法规结构是什么？

4.进行性肌肉骨化症市场主要供应商的市场占有率为何？

5.进入进行性肌肉骨化症市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 进行性肌肉骨化症的发生率增加
      • 提高医疗保健专业人员和公众对罕见疾病和遗传疾病的认识
    • 抑制因素
      • 进行进行性肌肉骨化症治疗的开发成本很高
    • 机会
      • 增加研发活动以开发新治疗方法
      • 政府对罕见疾病的资助和核准
    • 任务
      • 对进行性肌肉骨化症的认知较低
  • 市场区隔分析
    • 提供详细资讯：对 parvarotene 的需求不断增加，其抑制 FOP异位性骨化症的进展
    • 最终使用者：进行性肌肉骨化症药物经常在医院用于 FOP 的诊断、治疗和持续管理。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章进行性肌肉骨化症市场：透过提供

  • 药物类型
  • 过程

第七章进行性肌肉骨化症市场：依给药途径

  • 口服
  • 胃肠外的
  • 话题

第 8 章进行性肌肉骨化症市场：依最终用户

  • 医院
  • 调查机构
  • 专科诊所

第九章北美和南美的进行性肌肉骨化症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区进行性肌肉骨化症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的进行性肌肉骨化症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • FDA核准Ibsen 的进行性肌肉骨化症治疗
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-9E71DF483BA8

[181 Pages Report] The Fibrodysplasia Ossificans Progressiva Market size was estimated at USD 470.46 million in 2023 and expected to reach USD 494.59 million in 2024, at a CAGR 5.30% to reach USD 675.65 million by 2030.

Fibrodysplasia ossificans progressiva (FOP) is a rare, severe genetic disorder characterized by the gradual replacement of soft tissue, such as muscles, ligaments, and connective tissue, by bone (ossification). This process leads to bone-forming outside the skeleton, restricting movement. The disorder is caused by a mutation in the ACVR1 gene, which impacts the body's repair mechanism, causing fibrous tissues to be replaced by bone after damage or injury. Rising fibrodysplasia ossificans progressiva incidence rates worldwide are expanding the need for treatments associated with fibrodysplasia ossificans progressiva. The elevating awareness among healthcare professionals and the public, with increased funding and support from government bodies for rare diseases, is improving diagnostics and the availability of treatment options, subsequently supporting market growth. High R&D costs for developing effective treatments for FOP and stringent regulatory processes for approving drugs for rare diseases are hampering the market's growth. Increasing progress in genetic research and targeted therapy approaches that offer potential breakthrough treatments associated with fibrodysplasia ossificans progressiva creates opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 470.46 million
Estimated Year [2024] USD 494.59 million
Forecast Year [2030] USD 675.65 million
CAGR (%) 5.30%

Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP

Nonsteroidal anti-inflammatory drugs (NSAIDs) are often specified to manage pain and swelling associated with flare-ups in FOP patients. While these medications do not halt the progression of the disease, they can vastly improve the quality of life for affected individuals by reducing discomfort. Bisphosphonates are a class of medications that prevent the loss of bone mass. They are used to slow down the skeletal changes in FOP patients. The effectiveness of bisphosphonates in FOP is still under investigation, with research ongoing to better understand their role in managing the condition. Corticosteroids are used during the early stages of flare-ups to reduce inflammation and tissue swelling. Their use is typically short-term due to potential long-term side effects but can be crucial in managing acute phases of the condition. Palovarotene is a retinoic acid receptor gamma agonist that has shown promise in reducing the progression of heterotopic ossification in FOP. It represents a significant breakthrough in treating FOP, offering hope for improved management of this condition. Medication remains a cornerstone of FOP management, addressing symptoms, managing pain, and, in the case of drugs including, palovarotene, potentially slowing disease progression. The choice of medication requires careful consideration of the individual's condition and the phase of the disease. Occupational therapy plays a vital role in maintaining mobility and quality of life for individuals with FOP. Therapists work with patients to develop strategies for performing daily activities with minimal stress on affected areas, thus preventing flare-ups and managing the limitations imposed by the disease. Surgery in FOP patients is approached with great caution due to the risk of triggering further ossification. It is generally reserved for cases where skeletal abnormalities cause severe functional impairments or life-threatening problems that cannot be managed conservatively. Each case requires careful evaluation to balance the benefits of surgery against the potential for exacerbating the condition.

End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP

Hospitals represent a critical front-line end-user group in fibrodysplasia ossificans progressiva (FOP). These institutions serve as primary centers for diagnosis, treatment, and ongoing management of FOP. Given the complexity of FOP, hospitals often coordinate multidisciplinary care teams, encompassing specialists in genetics, orthopedics, and endocrinology, to address the diverse and progressive symptomology associated with the disease. Hospitals also play a pivotal role in providing emergency care for FOP patients who may suffer from flare-ups leading to immobility or respiratory issues. Research Institutes are integral to advancing our understanding and treatment of fibrodysplasia ossificans progressiva. They dive deep into FOP's genetic, molecular, and cellular underpinnings, striving to uncover novel therapeutic targets and strategies. These entities are the backbone of clinical trials assessing the efficacy and safety of novel treatments. Collaborations among research institutes and pharmaceutical manufacturers are vital for bringing innovative therapies from the bench to the bedside. Moreover, research institutes often spearhead educational initiatives to extend awareness and educate the medical community and public about FOP. Specialty Clinics play a unique role in the care ecosystem for fibrodysplasia ossificans progressiva. Often staffed by multidisciplinary teams with specific expertise in FOP, these clinics offer specialized care tailored to the complex needs of FOP patients. From genetic counseling and physiotherapy to advanced pain management and surveillance for disease progression, specialty clinics provide a continuum of care designed to improve quality of life and mitigate the complications associated with FOP. They also foster a community among patients and families, offering support beyond medical treatment.

Regional Insights

The market for fibrodysplasia ossificans progressiva (FOP) in the Americas is characterized by a robust research and development ecosystem, benefiting from advanced healthcare infrastructure and a strong emphasis on rare disease treatment. There are also multiple awareness programs and patient advocacy groups that support research funding and patient care. Regulatory incentives such as orphan drug designation by the FDA expedite the approval process for new treatments, making the Americas a critical region for FOP therapeutic development and commercialization. Asia-Pacific is witnessing a growing awareness and increasing diagnosis rates of rare diseases, including FOP. This market is gradually evolving with improved healthcare systems and increased healthcare spending in countries including China, Japan, and Australia. However, challenges such as limited access to treatment and a lack of specialized healthcare facilities for rare diseases prevail. The EMEA region's FOP market is diverse, with Europe leading in clinical research, drug development, and patient advocacy. European countries benefit from strong public healthcare systems and policies encouraging rare disease research, including substantial funding and incentives for orphan drug development. Collaborations between governments, research institutions, and pharmaceutical companies support the market. In contrast, the Middle East and Africa face more profound challenges, including lower awareness, scant research, and limited treatment access. However, ongoing efforts to establish better healthcare infrastructure and international collaborations for rare disease treatment are positive indicators for the market's future in African regions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fibrodysplasia Ossificans Progressiva Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fibrodysplasia Ossificans Progressiva Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fibrodysplasia Ossificans Progressiva Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Accord Healthcare, Inc, Amgen Inc., BioCryst Pharmaceuticals, Inc., bioMerieux S.A., Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Incyte Corporation, Ipsen Pharma, Merck & Co Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Fibrodysplasia Ossificans Progressiva Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Drug Type
      • Anti-inflammatory Medications
      • Bisphosphonates
      • Corticosteroids
      • Palovarotene
    • Treatment
      • Medication
      • Occupational Therapy
      • Surgery
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fibrodysplasia Ossificans Progressiva Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fibrodysplasia Ossificans Progressiva Market?

3. What are the technology trends and regulatory frameworks in the Fibrodysplasia Ossificans Progressiva Market?

4. What is the market share of the leading vendors in the Fibrodysplasia Ossificans Progressiva Market?

5. Which modes and strategic moves are suitable for entering the Fibrodysplasia Ossificans Progressiva Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of fibrodysplasia ossificans progressiva diseases
      • 5.1.1.2. Rising awareness among healthcare professionals and the public for rare and genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of fibrodysplasia ossificans progressiva treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
      • 5.1.3.2. Availability of government funding and approvals for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness for the fibrodysplasia ossificans progressiva
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
    • 5.2.2. End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Fibrodysplasia Ossificans Progressiva Market, by Offering

  • 6.1. Introduction
  • 6.2. Drug Type
  • 6.3. Treatment

7. Fibrodysplasia Ossificans Progressiva Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Fibrodysplasia Ossificans Progressiva Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Americas Fibrodysplasia Ossificans Progressiva Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fibrodysplasia Ossificans Progressiva Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fibrodysplasia Ossificans Progressiva Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET RESEARCH PROCESS
  • FIGURE 2. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET DYNAMICS
  • FIGURE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE FI